GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » 3-Year Revenue Growth Rate

HLVX (HilleVax) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is HilleVax 3-Year Revenue Growth Rate?

HilleVax's Revenue per Share for the three months ended in Dec. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of HilleVax's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, HilleVax's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HilleVax's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HilleVax's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where HilleVax's 3-Year Revenue Growth Rate falls into.


;
;

HilleVax 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

HilleVax  (NAS:HLVX) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

HilleVax 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of HilleVax's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

HilleVax Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
MGNX ASMB SAVA IFRX ARTV IOBT TCRX CRVO CABA BMEA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
321 Harrison Avenue, Boston, MA, USA, 02118
Website
https://www.hillevax.com
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Executives
Robert Hershberg director, officer: President and CEO 3005 FIRST AVENUE, SEATTLE WA 98121
Shane Maltbie officer: Chief Financial Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Aditya Kohli director, officer: Chief Operating Officer C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Frazier Life Sciences X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Astrid Borkowski officer: Chief Medical Officer C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Nanette Cocero director C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109
Fhmls X, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Gary Dubin director C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Jaime Sepulveda director C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109
Takeda Vaccines, Inc. 10 percent owner 75 SIDNEY STREET, CAMBRIDGE MA 02139
Shelley Chu director ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Fhmls X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Julie L. Gerberding director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David A Socks officer: CFO & Chief Business Officer C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130